NTRA - Natera, Inc.
| Previous Close | 25.16 |
| Open | 25.04 |
| Bid | 20.50 x 1800 |
| Ask | 25.95 x 1100 |
| Day's Range | 24.42 - 25.55 |
| 52 Week Range | 11.08 - 29.62 |
| Volume | 610,156 |
| Avg. Volume | 686,895 |
| Market Cap | 1.723B |
| Beta (3Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.15 |
| Earnings Date | Mar 11, 2019 - Mar 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.67 |
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of NTRA earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Natera Inc Earnings Call
- Simply Wall St.•11 days ago
What Kind Of Shareholder Owns Most Natera, Inc. (NASDAQ:NTRA) Stock?
A look at the shareholders of Natera, Inc. (NASDAQ:NTRA) can tell us which group is most powerful. Generally speaking...
- PR Newswire•14 days ago
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness SAN CARLOS, Calif. , June 3, 2019 /PRNewswire/ -- A new study demonstrates ...
- Zacks•26 days ago
Natera, Inc. (NTRA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Natera, Inc. (NTRA).
- PR Newswire•27 days ago
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test
Represents Major Commercialization Milestone SAN CARLOS, Calif. , May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California -based laboratories, has posted a favorable ...
- Zacks•28 days ago
OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%
OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Motley Fool•last monthNatera (NTRA) Q1 2019 Earnings Call Transcript
NTRA earnings call for the period ending March 31, 2019.
- Zacks•last month
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 8.47% and 0.63%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Natera: 1Q Earnings Snapshot
On a per-share basis, the San Carlos, California-based company said it had a loss of 54 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•last month
Natera Reports First Quarter 2019 Financial Results
SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for ...
- PR Newswire•last month
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
JAMA Oncology Study Suggests Potential for Natera's Signatera Test to Guide Treatment Decisions After Surgery SAN CARLOS, Calif. , May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ ...
- PR Newswire•last month
Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards
Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection SAN CARLOS, Calif. , May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced ...
- PR Newswire•last month
FDA Grants Breakthrough Device Designation to Natera's Signatera Test
Accelerated Regulatory Review Intended to Expedite Use of Test in Pharmaceutical Trials and Improve Upon Current Clinical Standards SAN CARLOS, Calif. , May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: ...
- Insider Monkey•last month
Did Hedge Funds Drop The Ball On Natera Inc (NTRA)?
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- PR Newswire•last month
Natera Announces First Quarter 2019 Earnings Conference Call
SAN CARLOS, Calif. , May 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release ...
- PR Newswire•2 months ago
Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , April 17, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 ...
- Benzinga•2 months ago
The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...
- PR Newswire•2 months ago
Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 ...
- PR Newswire•2 months ago
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signatera™ research-use-only (RUO) molecular residual disease (MRD) assay detected disease relapse up to two years earlier than imaging in patients with early-stage breast cancer.1 The new publication validates clinical performance of Signatera for recurrence monitoring and MRD assessment in breast cancer. The results were published online today in the latest issue of Clinical Cancer Research.
- Simply Wall St.•2 months ago
How Does Natera, Inc. (NASDAQ:NTRA) Affect Your Portfolio Volatility?
Anyone researching Natera, Inc. (NASDAQ:NTRA) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as fall...
- PR Newswire•2 months ago
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma
SAN CARLOS, Calif., April 10, 2019 /PRNewswire/ -- Natera, Inc. (NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA, using plasma samples from patients with cancer. The assay does not require tumor tissue and will interrogate approximately 20,000 genes from circulating tumor DNA (ctDNA) to detect somatic mutations, representing a significant increase in coverage over most commercially available fixed liquid biopsy panels.
- PR Newswire•3 months ago
Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test
Represents Major Reimbursement Milestone on Company's Path to Commercialization in 2019 SAN CARLOS, Calif. , March 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA ...
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within JD, Five9, Ambarella, Natera, Methanex, and Virtusa — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine
New Clinical Trial Adds to Growing Number of Studies Supporting Use of Signatera as a Potential Surrogate Endpoint SAN CARLOS, Calif. , March 26, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NTRA earnings conference call or presentation 12-Mar-19 8:30pm GMT
Q4 2018 Natera Inc Earnings Call
